A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

ABSTRACT:

Background

Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constitutively active androgen receptor splice variants (AR-Vs) or inhibiting other drug-resistance pathways (e.g., Wnt-signaling). Published pharmacokinetics data suggests that niclosamide has poor oral bioavailability, potentially limiting its use as a cancer drug. Therefore, we launched a Phase I study testing oral niclosamide in combination with enzalutamide, for longer and at higher doses than those used to treat helminthic infections.

Methods

We conducted a Phase I dose-escalation study testing oral niclosamide plus standard-dose enzalutamide in men with metastatic CRPC previous

SUBMITTER: Schweizer MT 

PROVIDER: S-EPMC5983471 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature